Biodexa Pharmaceuticals Plc appointed Fiona Sharp as Chief Financial Officer and Director effective January 5, 2026; she previously served as Group Financial Controller since December 2019. This is a significant event for the company, with a neutral sentiment from an equity investor perspective.